Johnson & Johnson (JNJ) : Mcnamara Financial Services has sold out all of its stake in Johnson & Johnson during the most recent quarter, according to the disclosure filed by the company on Apr 13, 2016 with the SEC. The investment management company has sold out 2,560 shares of Johnson & Johnson which is valued at $282,061.
Johnson & Johnson opened for trading at $110 and hit $111.1 on the upside on Monday, eventually ending the session at $110.93, with a gain of 0.68% or 0.75 points. The heightened volatility saw the trading volume jump to 77,72,549 shares. Company has a market cap of $306,096 M.
Other Hedge Funds, Including , Naples Global Advisors reduced its stake in JNJ by selling 516 shares or 2.64% in the most recent quarter. The Hedge Fund company now holds 19,012 shares of JNJ which is valued at $2,094,742. Johnson & Johnson makes up approx 0.87% of Naples Global Advisors’s portfolio.Banced Corp reduced its stake in JNJ by selling 226 shares or 3.18% in the most recent quarter. The Hedge Fund company now holds 6,890 shares of JNJ which is valued at $759,140. Johnson & Johnson makes up approx 1.32% of Banced Corp’s portfolio.Stewart Patten Co reduced its stake in JNJ by selling 1,707 shares or 0.69% in the most recent quarter. The Hedge Fund company now holds 245,304 shares of JNJ which is valued at $27,027,595. Johnson & Johnson makes up approx 5.39% of Stewart Patten Co’s portfolio.Bkd Wealth Advisors boosted its stake in JNJ in the latest quarter, The investment management firm added 150 additional shares and now holds a total of 32,958 shares of Johnson & Johnson which is valued at $3,631,312. Johnson & Johnson makes up approx 0.57% of Bkd Wealth Advisors’s portfolio.Charter Trust Co reduced its stake in JNJ by selling 1,757 shares or 0.88% in the most recent quarter. The Hedge Fund company now holds 198,293 shares of JNJ which is valued at $21,607,988. Johnson & Johnson makes up approx 2.65% of Charter Trust Co’s portfolio.
On the company’s financial health, Johnson & Johnson reported $1.68 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Apr 19, 2016. Analyst had a consensus of $1.65. The company had revenue of $17482.00 million for the quarter, compared to analysts expectations of $17491.02 million. The company’s revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.56 EPS.
Many Wall Street Analysts have commented on Johnson & Johnson. Company shares were Reiterated by RBC Capital Mkts on Apr 15, 2016 to “Outperform”, Firm has raised the Price Target to $ 122 from a previous price target of $114 .Johnson & Johnson was Upgraded by Goldman to ” Neutral” on Mar 14, 2016.
Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Companys primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Companys research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.